Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFZH49)

• Drug Name: Phenyl Boronic acid Drug Info
• Synonyms: Phenylboronic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 66827
  ChEBI ID: CHEBI:44923
  CAS Number: CAS 98-80-6
  TTD Drug ID: DMFZH49

Molecule-Related Drug Atlas

Drug(s) Targeting Fatty acid amide hydrolase (FAAH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[6]
Thiopental	DMGP8AX	Anaesthesia	9A78.6	Approved	[7]
JNJ-42165279	DM72GZO	Anxiety disorder	6B00-6B0Z	Phase 2	[8]
SSR411298	DMGTB2Q	Major depressive disorder	6A70.3	Phase 2	[9]
IW-6118	DMP42W1	Inflammation	1A00-CA43.1	Phase 2	[10]
PF-04457845	DMPRYU1	Liver disease	DB90-BD99	Phase 2	[11]
IPI-940	DMEIM5G	Pain	MG30-MG3Z	Phase 1	[12]
PMID29053063-Compound-11d	DMDRK68	N. A.	N. A.	Patented	[13]
Piperazine carbamic compound 1	DMZSYU4	N. A.	N. A.	Patented	[13]
Piperazine carbamic compound 2	DMMQ0ZO	N. A.	N. A.	Patented	[13]

Drug(s) Targeting Carbonic anhydrase I (CA-I)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[14]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[15]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[15]
Methazolamide	DM7J2TA	Glaucoma/ocular hypertension	9C61	Approved	[16]
Acetazolamide	DM1AF5U	Absence epilepsy		Approved	[15]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[17]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[18]
CG-100649	DMIKMA9	Arthritis	FA20	Phase 3	[19]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[17]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[20]

Drug(s) Targeting Carbonic anhydrase II (CA-II)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[14]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[21]
Dorzolamide	DMA17D0	Ocular hypertension	9C61.01	Approved	[22]
Chlorothiazide	DMLHESP	Chronic heart failure	BD1Z	Approved	[23]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[24]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[24]
Cyclothiazide	DMJ4AWC	Congestive heart failure	BD10	Approved	[25]
Ethinamate	DMK57GB	Insomnia	7A00-7A0Z	Approved	[26]
Benzthiazide	DMQWZ0H	High blood pressure	BA00	Approved	[27]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[17]

Drug(s) Targeting Carbonic anhydrase (CA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[28]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[29]
Quinethazone	DMWCOSR	Hypertension	BA00-BA04	Approved	[30]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[17]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[18]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[17]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[20]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[31]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[18]
PMID30074415-Compound-21	DM3NPOU	N. A.	N. A.	Patented	[32]

Drug(s) Targeting Carbonic anhydrase IV (CA-IV)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[14]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[33]
Brinzolamide	DMBAPFG	Ocular hypertension	9C61.01	Approved	[15]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[17]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[18]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[17]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[20]
Sodium pyruvate	DMST6A3	Asthma	CA23	Phase 1/2	[34]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[31]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[18]

Drug(s) Targeting Bacterial DD-carboxypeptidase (Bact vanYB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cefalotin	DMVYSLE	Bacteremia	1A73	Approved	[35]
B-Lactams	DMR8YD6	Bacterial infection	1A00-1C4Z	Approved	[36]
Cephalosporin	DM79XDW	Bacterial infection	1A00-1C4Z	Approved	[37]
Cefotaxime	DMEB837	Bacteremia	1A73	Approved	[38]
TD-1792	DMGKBZH	Skin infection	1F28-1G0Z	Phase 3	[39]
Cephalosporin C	DMYW3ZG	Discovery agent	N.A.	Investigative	[40]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[41]
D-Alanine	DMVIDQL	Discovery agent	N.A.	Investigative	[41]
3-boronobenzoic acid	DMRCJW0	Discovery agent	N.A.	Investigative	[1]
NITROCEFIN	DM7M5VY	Discovery agent	N.A.	Investigative	[24]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial DD-carboxypeptidase (Bact vanYB)	TTLP6GN	VANY_ENTFA	Inhibitor	[1]
Carbonic anhydrase (CA)	TTUNARX	NOUNIPROTAC	Inhibitor	[2]
Carbonic anhydrase I (CA-I)	TTHQPL7	CAH1_HUMAN	Inhibitor	[3]
Carbonic anhydrase II (CA-II)	TTANPDJ	CAH2_HUMAN	Inhibitor	[3]
Carbonic anhydrase IV (CA-IV)	TTZHA0O	CAH4_HUMAN	Inhibitor	[4]
Fatty acid amide hydrolase (FAAH)	TTDP1UC	NOUNIPROTAC	Inhibitor	[5]

References

• [1] Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors. J Med Chem. 2009 Oct 8;52(19):6097-106.
• [2] Carbonic anhydrase inhibitors: inhibition of the cytosolic human isozyme VII with anions. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3139-43.
• [3] Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9.
• [4] Carbonic anhydrase inhibitors: the membrane-associated isoform XV is highly inhibited by inorganic anions. Bioorg Med Chem Lett. 2009 Feb 15;19(4):1155-8.
• [5] Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60.
• [6] Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
• [7] The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003 Jul;139(5):1005-13.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [10] The Discovery and Development of Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Bioorg Med Chem Lett. 2011 August 15; 21(16): 4674-4685.
• [11] Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011 Feb 10;2(2):91-96.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1400).
• [13] A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
• [14] Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597).
• [17] Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
• [18] Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
• [19] Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12.
• [20] Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
• [21] Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26.
• [22] Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
• [23] Localization of diuretic effects along the loop of Henle: an in vivo microperfusion study in rats. Clin Sci (Lond). 2000 Apr;98(4):481-8.
• [24] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [25] Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82.
• [26] Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50.
• [27] Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961 Mar;131:271-4.
• [28] Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6.
• [29] Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
• [30] Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for th... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73.
• [31] Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5.
• [32] Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
• [33] Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
• [34] Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):573-8.
• [35] Binding of cephalothin and cefotaxime to D-ala-D-ala-peptidase reveals a functional basis of a natural mutation in a low-affinity penicillin-binding protein and in extended-spectrum beta-lactamases. Biochemistry. 1995 Jul 25;34(29):9532-40.
• [36] Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
• [37] A 1.2-A snapshot of the final step of bacterial cell wall biosynthesis. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1427-31.
• [38] Extended-spectrum cephalosporinases: structure, detection and epidemiology. Future Microbiol. 2007 Jun;2:297-307.
• [39] How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
• [40] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [41] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.